Fabry disease (α-Galactosidase a deficiency): Renal Involvement and enzyme replacement therapy

Contributions to Nephrology

Volumn 136, Issue , 2001, Pages 174-192

  Desnick, Robert J ^a   Wasserstein, Melissa P ^a   Banikazemi, Maryam ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

CLINICAL TRIAL; FABRY DISEASE; FEMALE; GENETICS; HUMAN; KIDNEY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MALE; PATHOLOGY; RENAL REPLACEMENT THERAPY; REVIEW;

ALPHA-GALACTOSIDASE; CLINICAL TRIALS; FABRY DISEASE; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; RENAL DIALYSIS;

EID: 0035537911     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (75)

1. Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase A deficiency: Fabry disease; in Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, pp 3733-3774.
2. Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H: Angiokeratoma corporis diffusum - Fabry's disease. Helv Med Acta 1967;34:67-83.
3. Von Scheldt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ: An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-399.
4. Ioannou YA, Bishop DF, Desnick RJ: Overexpression of human α-galactosidase A results in its intracellular aggregation, crystallization in lysosomes and selective secretion. J Cell Biol 1992;119:1137-1150.
5. Wang AM, Ioannou YA, Zeidner KM, Gotleb RW, Dikman S, Stewart CL, Desnick RJ: Generation of a mouse model with α-galactosidase A deficiency. Am J Hum Genet 1996;59:A208.
6. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ: Fabry disease: Preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001;68:14-25.
7. Eng CM, Banikazemi M, Gordon R, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dickman S, Stacy CB, Fallon JT, Brodie S, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-722.
8. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
9. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
10. Desnick RJ, Eng CM: Fabry disease: α-Galactosidase A deficiency; in Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austin KF (eds): Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 1999, pp 1812-1825.
11. Lyon M: Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 1961;190:372-373.
12. Desnick RJ, Simmons RL, Allen KY, Woods JE, Anderson CF, Najarian JS, Krivit W: Correction of enzymatic deficiencies by renal transplantation: Fabry's disease. Surgery 1972;72:203-211.
13. Levade T, Giordano F, Maret A, Marguery MC, Bazex J, Salvayre R: Different phenotypic expression of Fabry disease in female monozygotic twins. J Inherit Metab Dis 1991;14:105-106.
14. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R: Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 1978;13:223-235.
15. Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R: Renal pathologic lesions and functional alterations in a man with Fabry's disease. Am J Med 1973;55:415-425.
16. Sheth KJ, Roth DA, Adams MB: Early renal failure in Fabry's disease. Am J Kidney Dis 1983;2:651-654.
17. Pompen AWM, Ruiter M, Wyers JJG: Angiokertoma corporis diffusum (universale) Fabry, as a sign of internal disease: Two autopsy reports. Acta Med Scand 1947;128:234-255.
18. Desnick RJ, Dawson G, Desnick SJ, Sweeley CC, Krivit W: Diagnosis of glycosphingolipidoses by urinary-sediment analysis. N Engl J Med 1971;284:739-744.
19. Chatterjee S, Gupta P, Pyeritz RE, Kwiterovich POJ: Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease. Am J Clin Pathol 1984;82:24-28.
20. Morel-Maroger L, Ganter P, Ardaillou R, Cathelineau G, Richet G: Histochemical study of a lipid thesaurismosis with renal, cutaneous and neurologic involvement. Its relation to Fabry's angiokeratosis and familial renal cytodystrophy. Bull Mem Soc Méd Hôp Paris 1966;117:49-57.
21. McNary W, Lowenstein L: A morphological study of the renal lesion in angiokeratoma corporis diffusum universale (Fabry's disease). J Urol 1965;93:641.
22. Burkholder PM, Updike SJ, Ware RA, Reese OG: Clinicopathologic, enzymatic, and genetic features in a case of Fabry's disease. Arch Pathol Lab Med 1980;104:17-25.
23. Bishop DF, Grabowski GA, Desnick RJ: Fabry disease: An asymptomatic hemizygote with significant residual α-galactosidase A activity. Am J Hum Genet 1981;33:71A.
24. Clarke JT, Knaack J, Crawhall JC, Wolfe LS: Ceramide trihexosidosis (Fabry's disease) without skin lesions. N Engl J Med 1971;284:233-235.
25. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B, Ledvinova J, Belohlavek, Kral V, Dorazilova V: Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophie non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-455.
26. Ishii S, Sakuraba H, Suzuki Y: Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 1992;89:29-32.
27. Nagao Y, Nakashima H, Fukuhara Y, Shimmoto M, Oshima A, Ikari Y, Mori Y, Sakuraba H, Suzuki Y: Hypertrophie cardiomyopathy in late-onset variant of Fabry disease with high residual activity of α-galactosidase A. Clin Genet 1991;39:233-237.
28. Ogawa K, Sugamata K, Funamoto N, Abe T, Sato T, Nagashima K, Ohkawa S: Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol 1990;21:1067-1073.
29. Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, Desnick RJ, Suzuki Y: Identification of point mutations in the α-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 1990;47:784-789.
30. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, et al: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293.
31. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease. Ceramide trihexosidase deficiency. N Engl J Med 1967;276:1163-1167.
32. Kint JA: Fabry's disease: α-Galactosidase deficiency. Science 1970;167:1268-1269.
33. Clarke JTR, Wolfe LS, Perlin AS: Evidence for a terminal α-D-galactopyranosyl residue in galactosyl-galactosyl-glucosyl ceramide from human kidney. J Biol Chem 1971;246:5563-5569.
34. Hakomori SI, Siddiqui B, Li YT, Li SC, Hellerqvist CB: Anomeric structures of globoside and ceramide trihexoside of human erythrocytes and hamster fibroblasts. J Biol Chem 1971;246:2271-2277.
35. Sweeley CC, Klionsky B: Fabry's disease: Classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963;238:3148-3150.
36. Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ: Human α-galactosidase A: Nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 1986;83:4859-4863.
37. Bishop DF, Kornreich R, Eng CM, Ioannou YA, Fitzmaurice TF, Desnick RJ: Human α-galactosidase: Characterization and eukaryotic expression of the full-length cDNA and structural organization of the gene; in Salvayre R, Douste-Blazy L, Gatt S (eds): Lipid Storage Disorders. New York, Plenum, 1988, pp 809-822.
38. Kornreich R, Desnick RJ, Bishop DF: Nucleotide sequence of the human α-galactosidase A gene. Nucl Acids Res 1989;17:3301-3302.
39. Srivastava AK, McMillan S, Jermak C, Shomaker M, Copeland-Yates SA, Sossey-Alaoui K, Mumm S, Schlessinger D, Nagaraja R: Integrated STS/YAC physical, genetic, and transcript map of human Xq21.3 to q23/q24 (DXS1203-DXS1059). Genomics 1999;58:188-201.
40. Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, Desnick RJ: Fabry disease: Six gene rearrangements and an exonic point mutation in the α-galactosidase gene. J Clin Invest 1989;83:1390-1399.
41. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ: Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 1993;53:1186-1197.
42. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ: Fabry disease: Twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the α-galactosidase A gene. Hum Mol Genet 1994;3:1795-1799.
43. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ: Fabry disease: Thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997;3:174-182.
44. Ashton-Prolla P, Tong B, Shabbeer J, Eng CM, Desnick RJ: Twenty-two novel mutations in the α-galactosidase A gene and genotype/phenotype correlations including mild hemizygotes and severely affected heterozygotes. J Invest Med 2000;48:227-235.
45. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML: Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 1981;112:247-251.
46. Caggana M, Ashley GA, Desnick RJ, Eng CM: Fabry disease: Molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1. Am J Med Genet 1997;71:329-335.
47. Wise D, Wallace H, Jellinck E: Angiokeratoma corporis diffusum: A clinical study of eight affected families. Q J Med 1962;31:177.
48. Gordon KE, Ludman MD, Finley GA: Successful treatment of painful crises of Fabry disease with low-dose morphine. Pediatr Neurol 1995;12:250-251.
49. Philippart M: Treatment of painful crises of Fabry disease with morphine. Pediatr Neurol 1995;13:268.
50. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ: Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973;23:871-875.
51. Lenoir G, Rivron M, Gubler MC, Dufier JL, Tome FS, Guivarch M: Fabry's disease. Carbamazepine therapy in acrodyniform syndrome. Arch Fr Pediatr 1977;34:704-716.
52. Filling-Katz MR, Merrick HF, Fink JK, Miles RB, Sokol J, Barton NW: Carbamazepine in Fabry's disease: Effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 1989;39:598-600.
53. Cantor WJ, Daly P, Iwanochko M, Clarke JT, Cusimano RJ, Butany J: Cardiac transplantation for Fabry's disease. Can J Cardiol 1998;14:81-84.
54. Buhler FR, Thiel G, Dubach UC, Enderlin F, Gloor F, Tholen H: Kidney transplantation in Fabry's disease. Br Med J 1973;iii:28-29.
55. Maizel SE, Simmons RL, Kjellstrand C, Fryd DS: Ten-year experience in renal transplantation for Fabry's disease. Transplant Proc 1981;13:57-59.
56. Donati D, Novario R, Gastaldi L: Natural history and treatment of uremia secondary to Fabry's disease: A European experience. Nephron 1987;46:353-359.
57. Erten Y, Ozdemir FN, Demirhan B, Karakayali H, Demirag A, Akkoc H: A case of Fabry's disease with normal kidney function at 10 years after successful renal transplantation. Transplant Proc 1998;30:842-843.
58. Ramos EL, Tisher CC: Recurrent diseases in the kidney transplant. Am J Kidney Dis 1994;24:142-154.
59. Peces R: Is there true recurrence of Fabry's disease in the transplanted kidney? Nephrol Dial Transplant 1996;11:561.
60. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B: Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000;69:2337-2339.
61. Bannwart F: Fabry's disease. Light and electron microscopic cardiac findings 12 years after successful kidney transplantation (in German). Schweiz Med Wochenschr 1982;112:1742-1747.
62. Friedlaender MM, Kopolovic J, Rubinger D, Silver J, Drukker A, Ben-Gershon Z, Durst AL, Popovtzer MM: Renal biopsy in Fabry's disease eight years after successful renal transplantation. Clin Nephrol 1987;27:206-211.
63. Tsakiris D, Simpson HK, Jones EH, Briggs JD, Blinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F: Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 1996;11:4-20.
64. Donati D, Sabbadini M, Capsoni F, Baratelli L, Cassani D, de Maio A, Frattini G, Martegani M, Gastaldi L: Immune function and renal transplantation in Fabry's disease. Proc Eur Dialysis Transplant Assoc 1984;21:686.
65. Mosnier JF, Degott C, Bedrossian J, Molas G, Degos F, Pruna A, Potet F: Recurrence of Fabry's disease in a renal allograft eleven years after successful renal transplantation. Transplantation 1991;51:759-762.
66. Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, Schuchman E, Desnick RJ: Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol 1981;103:247-262.
67. Sinclair R: Origin of endothelium in human renal allograft. Br Med J 1972;11:15.
68. Popli S, Molnar ZV, Leehey DJ, Daugirdas JT, Roth DA, Adams MB, Cheng JC, Ing TS: Involvement of renal allograft by Fabry's disease. Am J Nephrol 1987;7:316-318.
69. Grunfeld JP, Le Porrier M, Droz D, Bensaude I, Hinglais N, Crosnier J: Renal transplantation in patients suffering from Fabry's disease. Kidney transplantation from a heterozygote subject to a subject without Fabry's disease. Nouv Presse Méd 1975;4:2081-2085.
70. Desnick RJ, Allen KY, Simmons RL, Woods JE, Anderson CF, Najarian JS, Krivit W: Fabry disease: Correction of the enzymatic deficiency by renal transplantation. Birth Defects Orig Artic Ser 1973;9:88-96.
71. Clarke JT, Guttmann RD, Wolfe LS, Beaudoin JG, Morehouse DD: Enzyme replacement therapy by renal allotransplantation in Fabry's disease. N Engl J Med 1972;287:1215-1218.
72. Kramer W, Thormann J, Mueller K, Frenzel H: Progressive cardiac involvement by Fabry's disease despite successful renal allotransplantation. Int J Cardiol 1985;7:72-75.
73. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, Quirk JM, Dekaban AS: Replacement therapy for inherited enzyme deficiency. Use of purified ceramide trihexosidase in Fabry's disease. N Engl J Med 1973;289:9-14.
74. Desnick RJ, Dean KJ, Grabowski G, Bishop DF, Sweeley CC: Enzyme therapy in Fabry disease: Differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic α-galactosidase A isozymes. Proc Natl Acad Sci USA 1979;76:5326-5330.
75. Mapes CA, Anderson RL, Sweeley CC, Desnick RJ, Krivit W: Enzyme replacement in Fabry's disease, an inborn error of metabolism. Science 1970;169:987-989.